Claimable Blog

Getting denied coverage for Humira is disorienting because the denial could mean very different things depending on your situation.

If you're a new patient, it likely means your insurer wants you to try cheaper alternatives first. If you've been stable on Humira for months or years, it might mean your insurer removed it from the formulary entirely and is pushing you toward a biosimilar you never asked for. And while biosimilars are clinically similar to Humira, "similar" doesn't mean identical — some patients experience differences in side effects, delivery devices, or how well the medication controls their condition.

Since 2024, all three major pharmacy benefit managers have been removing brand-name Humira from their commercial formularies. CVS Caremark dropped it in April 2024. Express Scripts followed for 2025. OptumRx did the same. In their place: biosimilars like Hyrimoz, Amjevita, Cyltezo, and Hadlima. The result is a wave of denials that simply didn't exist two years ago.

The good news is that you can appeal, and appeals work far more often than most people realize. The right approach depends on which type of denial you're facing. And because Humira is approved for so many conditions — rheumatoid arthritis, Crohn's disease, psoriasis, and more — the step therapy requirements can vary dramatically depending on your diagnosis.

This article explains why your Humira coverage was denied, how to match your denial type to the right response, and what to include in an appeal that actually gets results.

Why Insurance Denies Humira Coverage

Before you do anything else, identify the specific reason your insurer denied coverage. The denial reason determines your entire appeal strategy, and submitting the wrong type of response wastes time and can exhaust your limited appeal opportunities.

Broadly, Humira denials fall into two camps: patients who are already stable on Humira and are being forced onto a biosimilar, and new patients trying to get coverage for the first time. Both face real barriers, but the barriers are different, and so are the solutions.

What Makes Humira Denials Different from Other Medications

Humira is approved for nine or more autoimmune disorders, including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, severe chronic plaque psoriasis, severe hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. Each condition has completely different step therapy requirements. A denial for a Crohn's patient and a denial for a psoriasis patient may use identical language but require totally different appeal strategies. A blanket response that doesn't address your specific condition's requirements will almost certainly fail.

Humira is also a biologic, not a pill. That means safety screenings — a TB test, a hepatitis B panel — are required before treatment can start. Missing or incomplete lab results are one of the most common and most preventable reasons for Humira prior authorization denials. If your denial traces back to missing screenings, you may not need a formal appeal at all. A corrected resubmission with the lab results included can resolve it.

And then there's the biosimilar shift. Many Humira denials in 2025 and 2026 aren't about whether you need adalimumab. They're about whether your insurer will pay for the brand-name version or require you to use a lower-cost alternative. When your insurer removes Humira from its formulary and replaces it with Hyrimoz or Amjevita, that's a business decision, not a medical one.

The Denial Types You're Most Likely to Encounter

Most articles about Humira denials list reasons using the language insurers put in their letters. That's not especially helpful. What matters is what the denial actually means for you and how it shapes your next move.

A note before you start building your appeal: not every denial requires one. If your denial traces back to a correctable administrative error — missing safety screenings, an incorrect ICD-10 code, or an outdated billing code — a corrected resubmission is often faster and more effective than a formal appeal. One common billing issue right now: the HCPCS code for adalimumab changed from J0135 to J0139 as of January 2025. If your provider's billing system hasn't been updated, that alone can trigger a denial.

Formulary Change and Biosimilar Switch Denials

This is the denial type driving the most confusion and frustration right now. If you've been stable on Humira and received a letter saying it's no longer on your plan's formulary, you're not alone.

CVS Caremark removed brand Humira from its major national commercial formularies in April 2024, replacing it with biosimilars. Express Scripts did the same beginning in 2025, and OptumRx followed with its own biosimilar-first strategy. The practical effect: millions of patients who had stable coverage woke up to letters telling them their medication was no longer preferred.

The insurer's position isn't irrational. Biosimilars are clinically similar to Humira, and for many patients, switching works fine. But "many patients" isn't all patients. A 2026 analysis of Truveta electronic health record data found that among patients who switched from brand Humira to a biosimilar, 13.2% ultimately switched back to the original. Nearly 40% of those switchbacks happened within 30 days, suggesting early dissatisfaction, side effects, or problems with the transition.

If you have a clinical reason for staying on brand Humira, the strongest arguments for a formulary exception include: adverse reactions to a biosimilar's inactive ingredients or delivery device, a documented history of disease flares during medication switches, immunogenicity concerns such as developing antibodies during transitions, and adherence and consistency factors for chronic conditions where stability matters.

It's also worth knowing that manufacturer support programs are evolving alongside this biosimilar transition. AbbVie's patient assistance landscape for Humira is shifting as biosimilars become the standard formulary option, which makes understanding your appeal rights more important than ever. If copay support that previously helped cover your costs is changing, an approved appeal that restores insurance coverage is the most reliable path forward.

Step Therapy Required (Conventional Medications)

Step therapy means your insurer requires you to try and fail on older, cheaper medications before approving Humira. Even when your doctor has clinical reasons for prescribing it directly.

What makes this especially complicated for Humira is that step therapy requirements are completely different depending on your diagnosis. A rheumatoid arthritis (RA) patient typically needs to fail on one or two conventional DMARDs like methotrexate. A plaque psoriasis patient may need to fail topical agents and a conventional systemic. A patient with ankylosing spondylitis usually needs to try two or more NSAIDs first. Knowing what your insurer expects for your specific condition is essential before you build your appeal.

"Failure" doesn't always mean the drug didn't work. Side effects, contraindications, and medical reasons a drug is inappropriate all count. Methotrexate, for example, is contraindicated in pregnancy and may not be safe for patients with liver disease. If your doctor knows you can't take a required step therapy drug, that should be documented clearly in your appeal rather than forcing you through a trial that's medically inappropriate.

When an insurer demands you fail on conventional therapies before accessing Humira, they may be contradicting leading medical society guidance. The American College of Rheumatology's 2021 guidelines for RA support biologic therapy for patients who don't achieve their treatment target on conventional DMARDs like methotrexate. If you've already tried and failed the medications your insurer's step therapy requires, citing these guidelines puts the insurer's demand for additional steps in tension with the clinical evidence. The 2025 American College of Gastroenterology guidelines for Crohn's disease go further, explicitly recommending against the traditional step-up approach and supporting early use of advanced therapies for patients with moderate-to-severe disease. Citing these guidelines in your appeal is a powerful argument at any stage of the process.

Biosimilar Step Therapy

This is distinct from conventional step therapy. Here, the insurer will cover adalimumab — they just want you to try a preferred biosimilar (typically Hyrimoz, Amjevita, or Cyltezo) before brand Humira.

The practical question is straightforward: is there a clinical reason you specifically need the brand? If you've been stable on brand Humira and have documented reasons why switching poses risk — adverse reactions, immunogenicity concerns, prior failed switches — then document those reasons thoroughly and appeal. If you haven't tried a biosimilar and don't have a clinical contraindication, trying the preferred biosimilar may be the fastest path to treatment.

PA Requirements Not Met (Not Medically Necessary)

This denial often means the initial submission was too thin, not that the insurer fully reviewed your case and made a considered medical judgment. Common gaps include not specifying disease severity with objective measures (DAS28 scores for rheumatoid arthritis, CDAI for Crohn's, PASI or BSA for psoriasis), not listing prior failed therapies with dates and specific outcomes, and not explaining how your symptoms and disease progression make Humira the appropriate next step for your situation.

Because Humira treats so many conditions, the documentation requirements differ by diagnosis. A prior authorization that doesn't clearly link your specific condition, its severity, your treatment history, and the insurer's criteria for that indication will almost always trigger this denial. The fix is usually more thorough documentation, not a different argument.

How to Appeal a Humira Denial (Step by Step)

Appeals work far more often than most people think. Insurance companies have spent decades conditioning patients to accept "no" as final. It's not. Fewer than 1% of insurance denials are ever appealed, and insurers count on that. When patients do appeal with the right evidence and documentation, overturn rates are significant.

Step 1: Read Your Denial Letter Carefully

Your denial letter is required by law to include the reason for denial, your appeal rights, and your deadline to appeal. Read it closely and identify which denial type from the table above matches your situation. If anything in the letter is unclear, you have the right to request and review your full claim file from your insurer.

Pay close attention to your deadline. Most commercial insurance plans allow 180 days to file an appeal, but UnitedHealthcare gives just 65 calendar days for commercial plan member-initiated appeals — the shortest window among major insurers. Medicare Advantage plans follow CMS rules at 60 days. Missing your deadline forfeits your appeal rights regardless of how strong your case is.

Step 2: Understand That You Can Appeal — Not Just Your Doctor

Many patients assume their doctor has to handle the appeal. Your doctor's prior authorization or provider appeal is one process. Your patient-initiated appeal is a separate process with its own protections. Here's why you should appeal yourself, not just leave it to your doctor.

Patient appeals carry stronger legal protections than provider appeals: mandated response timelines, the right to external review by an independent third party, and multiple levels of appeal. If your doctor's PA was denied, your appeal is a separate opportunity. Use it.

Step 3: Confirm Your Clinical Documentation Is Complete

Before building your appeal, run through the basics. Is the diagnosis coded correctly with current ICD-10 codes for your specific indication? Are all required safety screenings (TB test, hepatitis B panel) documented and included? Is the billing code current (J0139 as of January 2025, not the old J0135)?

For patients being switched off brand Humira: is your doctor willing to document your clinical stability on the current medication with specific metrics? Disease activity scores, lab values, and functional assessments all strengthen an appeal for continuity of care.

If the issue is a correctable administrative error, a resubmission may resolve it without a formal appeal, and it's faster.

Step 4: Get a Letter of Medical Necessity

This is the single most important document in your appeal. A strong letter of medical necessity from your prescribing physician should include your diagnosis with ICD-10 codes and current disease severity scores, your full prior medication history with specific reasons each therapy was stopped (inefficacy, side effects, contraindications), and clear clinical rationale for why Humira is the appropriate treatment.

For biosimilar switch appeals specifically, the letter should also document your clinical improvement on brand Humira with measurable outcomes and explain why switching introduces risk for your situation.

If your doctor hasn't written one before or seems unsure what to include, be direct. Offer to provide an outline of what insurers typically look for, or review how to talk to your doctor about a denial so you're prepared for the conversation. Many physicians are willing to write a strong appeal letter but don't always know the specific documentation that moves the needle with insurance reviewers.

Step 5: Build Your Appeal Package

A complete appeal package brings together four components:

Your cover letter states what you're appealing, which denial you're responding to, and what outcome you're requesting.

Your letter of medical necessity from your physician provides the clinical backbone.

Your clinical documentation includes relevant medical records, lab results, imaging, and disease severity assessments. Reference authoritative peer-reviewed clinical guidelines where they support your case: ACR guidelines for rheumatoid arthritis, AGA guidelines for Crohn's disease and ulcerative colitis, AAD guidelines for psoriasis and hidradenitis suppurativa.

Your personal statement explains how the denial affects your daily life, your health, and your ability to function. This is where you tell your story in your own words. Insurers are required to consider all submitted evidence during an appeal, and a clear personal narrative about the real-world impact of losing your medication adds weight that clinical documents alone can't provide.

Together, these form the three pillars of a winning appeal: your story, the clinical evidence, and the policy and legal analysis that shows your situation meets the plan's own criteria.

Step 6: Submit and Track

Submit your appeal according to the instructions in your denial letter. Your insurer must respond within 30 days for a standard internal appeal, or within 72 hours for an urgent or expedited appeal (when your health would be seriously jeopardized by waiting).

Keep records of everything: your submission method, date, confirmation numbers, and the name of anyone you speak with. If you submit by fax, keep the transmission confirmation. If you mail it, use certified mail with return receipt. If you don't receive a response within the required timeframe, here's what to do if you haven't heard back about your appeal.

Step 7: Escalate If Needed

If your internal appeal is denied, you have the right to an external review by an independent third party. This is a reviewer who evaluates the medical justification for your treatment, not whether the insurer wants to pay for it. External reviews are binding on the insurer in most states.

Some states also have additional protections worth knowing about. Several states have step therapy exception laws, and a growing number have enacted protections related to non-medical switching of biologic therapies. Check whether your state offers these protections before assuming you've exhausted your options.

Don't give up after one "no." The appeals process is designed with multiple levels for a reason. Persistence is part of the strategy, and each level of appeal brings a fresh set of eyes to your case. If you're feeling discouraged, here's why you shouldn't give up after a denied appeal.

An Easier Path: Let Claimable Handle Your Humira Appeal

If navigating this process feels overwhelming, or you don't have the time to research insurer policies and build a clinical case from scratch, Claimable can handle it for you.

Here's how it works:

1. Answer a few questions about your Humira denial and medical history.
2. We build your case using our database of millions of clinical studies, insurer policies, and legal standards.
3. We create a fully customized appeal package with your personal story, clinical evidence, and policy analysis.
4. We submit it for you — faxed and mailed directly to your insurer.
5. We guide you through escalation if needed.

Over 80% of Claimable appeals succeed, with most cases resolved in 10 days or less.

Appealing with Claimable for Humira costs $39.95. No success fees, no hidden costs, just a flat fee. When brand Humira can cost nearly $7,000 per month without insurance coverage, the math is simple.

Start your Humira appeal →

Appeal Timelines: How Long Does a Humira Appeal Take?

Typical timelines for each stage of the Humira insurance appeal process.

The faster you submit a complete, well-documented appeal, the faster you'll get a decision. The average Claimable appeal gets a response in just 10 days.

Frequently Asked Questions

Why was my Humira denied if my plan used to cover it?

Since 2024, all three major pharmacy benefit managers — CVS Caremark, Express Scripts, and OptumRx — have removed brand Humira from their commercial formularies in favor of lower-cost biosimilars. Your plan may still cover adalimumab, but the prior authorization process for the brand-name version now typically requires a formulary exception with clinical justification. "Covered" and "approved without a fight" are no longer the same thing for Humira.

Can I appeal a Humira denial myself, or does my doctor have to do it?

You can appeal yourself. Patient-initiated appeals are a separate process from provider appeals, and they carry their own legal protections including mandated response timelines and the right to external review. If your doctor's prior authorization was denied, your patient appeal is an additional opportunity, not a duplicate.

What if my insurer wants me to switch to a Humira biosimilar?

It depends on your clinical situation. If you've been stable on brand Humira and have documented reasons why switching poses risk — adverse reactions to a biosimilar, disease flares during prior medication changes, immunogenicity concerns — that's a strong case for a formulary exception. If you haven't tried a biosimilar and don't have a clinical contraindication, trying the preferred biosimilar may be the fastest path to treatment. Either way, understanding your options before responding to the denial is important.

My insurance changed my Humira coverage mid-year. Is that legal?

Insurers can update their formularies, and many did so aggressively in 2024 and 2025 as biosimilar competition expanded. However, some states have enacted step therapy protections and non-medical switching restrictions that may limit an insurer's ability to force patients off stable biologic therapy for purely cost-driven reasons. Check whether your state has these protections, and reference them in your appeal if applicable.

Is it worth appealing a Humira denial?

Yes. Fewer than 1% of insurance denials are ever appealed, and insurance companies count on patients accepting the initial "no." But when patients appeal with proper clinical documentation, clear evidence of medical necessity, and an understanding of their legal rights, overturn rates are significant. The process takes effort, but the alternative — abandoning a treatment that manages a serious chronic autoimmune disorder — carries real health consequences.

Claimable's physician-led team has helped patients recover over $30 million in care access by fighting insurance denials. We're SOC 2 Type II certified and HIPAA compliant. Learn more about how Claimable works →

Your doctor prescribed Wegovy because it's the right treatment for you. Your insurer disagreed. And if you're wondering whether it's even worth fighting back, it is, and this guide will show you exactly how.

Wegovy denials are extremely common, especially for the weight management indication. The 2025 KFF Employer Health Benefits Survey found that a majority of large employers (57%) still don't cover GLP-1 medications for weight loss. Even among the biggest firms (5,000+ workers), only 43% offer coverage. On ACA Marketplace plans, roughly 1% of formularies include Wegovy. The coverage gaps amount to a public health problem hiding behind paperwork. Nearly half of patients abandon treatment entirely after a denial, walking away from medications their doctors determined they need.

What the insurance industry doesn't expect is for you to do something about it. Fewer than 1% of denied claims ever get appealed, a statistic that saves insurers billions every year. But that number says more about how confusing the appeals process is than how hopeless it is. When patients actually push back with the right evidence, overturn rates are dramatically higher. We see this every day: Claimable's appeals succeed over 80% of the time in established conditions.

Knowing what kind of denial you're dealing with matters, because the strategy for overturning a blanket plan exclusion looks nothing like the strategy for a step therapy requirement or a documentation gap. This guide covers all of them, including the specific denial types, the clinical and legal arguments that win, and the exact steps to build an appeal that gets results.

Why Insurance Companies Deny Wegovy Coverage

Before you do anything else, you need to understand the specific reason your insurer denied coverage. The evidence you gather, the arguments you make, and the escalation path you follow all depend on this. Misidentifying your denial type is one of the fastest ways to waste a limited appeal opportunity.

What We See Across Thousands of Appeals

Denial letters are written in insurer language designed to sound final. They're not. Here's how to decode the most common denial types, what they actually mean for your situation, and where to start:

Blanket Plan Exclusion Denials

This is the denial type that makes people feel the most stuck, and understandably so. Your plan made a cost decision, not a clinical one. But Wegovy's FDA-approved label now extends well beyond weight management, covering cardiovascular risk reduction, MASH with liver fibrosis, and (as of March 2026) a higher 7.2 mg dose. A weight loss exclusion still leaves several doors open.

Your options:

Employer-sponsored plans: Talk to HR directly. Many employers adopted these exclusions before the cardiovascular and MASH data existed, and some are willing to revisit the policy, particularly when presented with the SELECT trial evidence showing Wegovy reduces the risk of heart attack, stroke, and cardiovascular death. Frame the request around healthcare outcomes and long-term cost avoidance, not "weight loss coverage."

The cardiovascular pathway: If you have established cardiovascular disease (previous heart attack, stroke, or peripheral arterial disease), Wegovy's CV indication may fall outside the weight loss exclusion entirely. This is the only weight management medication with this FDA approval, and it creates a distinct clinical category from weight management. This pathway is also relevant for Medicare Part D: the Treat and Reduce Obesity Act, signed into law in late 2025, requires Part D plans to cover at least one FDA-approved anti-obesity medication effective April 2026, and Wegovy's CV indication may offer an even earlier coverage pathway for beneficiaries with established heart disease.

The MASH pathway: If you have metabolic dysfunction-associated steatohepatitis with liver fibrosis, Wegovy is FDA-approved for this condition as of August 2025. A MASH-coded prescription is a different clinical category from a weight management prescription, and your plan may cover liver disease treatments even while excluding weight loss drugs.

Self-pay options while you appeal: Novo Nordisk offers Wegovy through NovoCare Pharmacy while you appeal. The oral pill starts at $149/month for starting doses. For injections, new patients can access starting doses at $199/month for their first two fills (offer available through June 30, 2026), then $349/month for standard doses or $399/month for the higher-dose Wegovy HD 7.2 mg. The Wegovy savings program can further reduce costs for commercially insured patients.

Not Medically Necessary Denials

This denial rarely reflects a genuine clinical judgment. It usually means the PA submission lacked documentation, and it's one of the most commonly overturned denial types on appeal.

What a strong submission includes: your baseline BMI before starting any treatment (not your current weight if medication has already helped, since insurers will use a lower number against you), a full accounting of comorbidities, prior weight loss interventions, relevant lab work, and a clear clinical rationale for why Wegovy specifically is the appropriate treatment.

Initial PA submissions are frequently bare-bones because prescribers are pressed for time. That 15-minute appointment doesn't leave much room for the kind of documentation that moves an insurer. If yours was thin, a resubmission with thorough documentation can change the outcome entirely.

Step Therapy Denials

Step therapy is the insurer's way of making you prove that cheaper options failed before they'll pay for the one your doctor actually prescribed. For Wegovy, that usually means trying Contrave, Saxenda, or phentermine, and some plans also require a formal weight management program.

The critical detail most patients miss: "failure" has a broad medical definition that works in your favor. You don't have to prove the medication did literally nothing. Intolerable side effects (heart palpitations on phentermine, nausea on Saxenda, mood changes on Contrave) count. So does a contraindication based on your medical history, even if you never took a single dose, and so does a weight management program that didn't produce or sustain clinically meaningful results.

The argument that wins: If there's a legitimate clinical reason the required alternatives are inappropriate, your doctor can request a step therapy exception. This argument is strongest if you have cardiovascular disease, since Wegovy is the only weight management medication with proven CV risk reduction from the SELECT trial. Nothing else in the step therapy chain carries that indication.

If you haven't tried the required alternatives and they're medically appropriate for you, completing the step therapy and documenting the results is sometimes the fastest path to approval.

Not on Formulary Denials

Every plan has a list of "preferred" drugs, and yours doesn't include Wegovy. This is typically a business decision about which drugs the insurer has negotiated pricing for.

The argument that wins: Request a formulary exception. Every insurer is required to have a process for non-formulary drugs that are medically necessary. Your case is stronger if you can show the formulary alternatives failed, caused side effects, are contraindicated, or don't cover a clinical need that Wegovy's label supports (cardiovascular risk reduction, MASH, or the specific weight management profile you need).

Sometimes the issue is that the insurer would prefer you take a different GLP-1 rather than rejecting Wegovy outright. If that's your situation, the clinical differentiation matters: document your response to Wegovy, any cardiovascular history or risk factors, and your prescriber's clinical rationale for why Wegovy specifically is the right choice. If you've already been stable on Wegovy and responding well, that continuity of care strengthens your case further.

One important detail: if your pharmacy benefits are managed by CVS Caremark, Wegovy has been their preferred GLP-1 for weight management since July 2025. If you're still getting a formulary denial through CVS Caremark, the block is likely coming from your employer's plan design, not the PBM, which means the conversation needs to happen with HR.

PA Requirements Not Met

This denial means the insurer claims you didn't meet one or more of their coverage requirements. Those rules may include BMI thresholds (typically 30 or higher, or 27 or higher with a comorbidity), weight management program participation, prior medication attempts, or specific comorbidity documentation.

That doesn't always mean you actually fail the criteria. Insurers sometimes apply rules incorrectly, overlook submitted documentation, or enforce requirements that exceed what medical evidence supports. Review each criterion against your actual records and address any gaps or misapplied rules directly in your appeal.

How to Appeal a Wegovy Denial: Step by Step

A denial is an opening position, and the appeals process exists specifically because denials are often wrong.

Step 1: Read Your Denial Letter Carefully

Your denial letter is required by law to include: the specific reason for denial, your appeal rights, and the deadline to file.

Find your deadline first. Most commercial plans give 180 days, but there are exceptions: UnitedHealthcare allows just 65 days for many plan types, and Medicare Advantage plans follow CMS guidelines of 60 days. Missing the deadline means you won't be allowed to appeal, so move quickly.

Step 2: Know That You Have Your Own Appeal Rights On Top of Your Doctor's

Your provider can (and should) appeal on the clinical side by resubmitting documentation, writing a letter of medical necessity, and requesting peer-to-peer review. But you also have the right to file your own appeal as the patient, and it runs on a separate track with its own protections.

Why this matters: Patient-initiated appeals come with guaranteed response timelines, external review rights, and multiple appeal levels that provider-level appeals may not offer. Use both tracks: your doctor makes the clinical case while you exercise your independent rights. If your prescriber's prior authorization was denied, that doesn't close the door on your side of the process.

Step 3: Get a Letter of Medical Necessity

A letter of medical necessity (LMN) from your prescribing physician is the single most important document in your appeal package.

What a strong LMN includes: your diagnosis codes and clinical history, baseline BMI and weight trajectory, documented comorbidities (with cardiovascular disease, MASH, sleep apnea, and prediabetes being especially relevant for Wegovy appeals), a summary of prior treatments and why they were insufficient, supporting clinical evidence like the STEP trials for weight management, the SELECT trial for cardiovascular outcomes, and the ESSENCE trial for MASH, and a clear explanation of why Wegovy specifically, rather than just "a GLP-1," is the right choice.

How to ask: Be direct with your doctor. "My insurance denied Wegovy. Would you be willing to write a letter of medical necessity for my appeal? I can provide information on what the insurer typically looks for." If your doctor's office hasn't written many of these, offering to share a template can improve the quality and completeness of the letter.

Step 4: Build Your Appeal Package

A complete submission should include a cover letter summarizing your request, the LMN, supporting clinical documentation (labs, visit notes, cardiovascular risk profile, weight history), and a personal statement describing how the denial has affected your health and daily life.

A winning appeal brings together three elements:

Your story: How your condition affects your ability to work, sleep, and care for your family. If you have cardiovascular disease, what it means to be denied a medication proven to reduce heart attack and stroke risk. Reviewers are people; give them context that data alone can't convey.

Clinical evidence: Reference the relevant trials from the FDA Profile section below: STEP 1 for weight management, SELECT for cardiovascular risk reduction, ESSENCE for MASH, STEP UP for the higher-dose 7.2 mg option, or OASIS 4 for the oral formulation. Match the evidence to your specific situation and indication.

Policy and legal analysis: How your situation meets your plan's own coverage criteria, relevant state laws, and federal protections like the ACA's appeal and external review requirements. If the insurer's denial contradicts their published criteria or ignores submitted documentation, call it out specifically.

Step 5: Submit and Track

For internal appeals: Submit to your insurer per the instructions in your denial letter. They're required to respond within 30 days for standard appeals (72 hours for urgent/expedited appeals).

Keep records: Document when you submitted, how (fax, mail, portal), confirmation numbers, and the name of anyone you speak with. Insurers lose things. Having a paper trail protects you.

Step 6: Escalate If Needed

A denied internal appeal isn't the end. You have the right to request an external review by an independent reviewer who has no relationship with the insurer. External reviews evaluate the clinical merits of the denial against objective evidence, not the insurer's internal cost calculations, and they regularly overturn denials.

Other escalation options include filing a complaint with your state's Department of Insurance, exploring additional legal options for employer-sponsored ERISA plans, or escalating to the Office of Personnel Management for federal employee plans.

Don't give up after one "no." The system is designed to make you quit. Persistence is part of the strategy.

Wegovy's Expanding FDA Profile: Why It Matters for Your Appeal

Wegovy now has a broader FDA-approved label than any other GLP-1 for weight management, and that broader label gives you more angles in an appeal.

Chronic weight management (approved June 2021): For adults with obesity (BMI of 30 or higher) or overweight with at least one comorbidity (BMI of 27 or higher), and for adolescents aged 12 and older with obesity. The STEP 1 trial demonstrated nearly 15% average body weight loss at 68 weeks, with more than 86% of participants losing at least 5% and roughly one-third losing 20% or more.

Cardiovascular risk reduction (approved March 2024): For adults with established cardiovascular disease and either obesity or overweight, to reduce the risk of heart attack, stroke, and cardiovascular death. Based on the SELECT trial, which enrolled over 17,600 participants across 41 countries and showed a 20% reduction in major adverse cardiovascular events. No other weight management medication carries this indication.

MASH (approved August 2025): For adults with metabolic dysfunction-associated steatohepatitis and moderate-to-advanced liver fibrosis. First and only GLP-1 approved for this condition, based on the ESSENCE trial.

Higher dose / Wegovy HD (approved March 2026): The 7.2 mg injection, which demonstrated approximately 21% average weight loss over 72 weeks in the STEP UP trial, with over 90% of participants achieving at least 5% weight loss and about a third losing 25% or more. Available nationwide since April 2026.

Oral formulation / Wegovy pill (approved December 2025): Semaglutide 25 mg oral tablet, the first oral GLP-1 for chronic weight management and cardiovascular risk reduction. The OASIS 4 trial showed 16.6% mean weight loss at 64 weeks among adherent participants. Available through pharmacies since January 2026, with self-pay pricing through NovoCare starting at $149/month for starting doses.

If your plan excludes weight loss drugs but covers cardiovascular treatment, the SELECT data opens a door. If you have MASH, you're dealing with a liver disease indication, not a weight loss one. And if your injectable Wegovy was denied, the oral formulation may face different coverage criteria.

How Long Does a Wegovy Appeal Take?

The single biggest factor in speed is completeness. Appeals that include everything (LMN, supporting documentation, personal statement, clinical evidence) move faster than submissions that trigger back-and-forth requests for additional information. In some cases, Claimable submits appeals to both internal and external review simultaneously to compress the timeline.

An Easier Path: Let Claimable Handle Your Appeal

If navigating this process feels overwhelming, or if you've been through a round of denials and need a stronger approach, Claimable can help.

Here's how it works: you answer a few questions about your Wegovy denial and medical history, and we build a fully customized appeal using our database of millions of clinical studies, insurer policies, and legal standards. The appeal package includes your personal narrative, clinical evidence matched to your specific situation, and a policy and legal analysis targeting your insurer's reasoning. We submit directly to your insurer and guide you through escalation if needed.

Thousands of GLP-1 appeals have taught us how each major insurer and PBM operates. We know which arguments work, which escalation paths are effective, and where the pressure points are.

Appealing with Claimable is $39.95 for Wegovy. No success fees, no hidden costs. For most patients, it's the difference between staying on a treatment that's working and abandoning it because the system made it too hard to fight.

Start your Wegovy appeal →

FAQs

Can I file my own appeal, or is that my doctor's job? Yes, and you should. Patient-initiated appeals run on a separate track from provider appeals with their own legal protections, mandated timelines, and external review rights. See Step 2 of the appeal guide above.

What's the difference between Wegovy and Ozempic? Same active ingredient (semaglutide), different FDA approvals and dosing. Wegovy is approved for chronic weight management (at 2.4 mg, 7.2 mg, and 25 mg oral), cardiovascular risk reduction, and MASH. Ozempic is approved for type 2 diabetes (at doses up to 2 mg). Insurance coverage often hinges on which diagnosis code is submitted; Ozempic gets approved more easily because diabetes indications face fewer coverage barriers.

Does Wegovy have a cardiovascular indication? Yes. It's the first and only weight management medication FDA-approved to reduce the risk of heart attack, stroke, and cardiovascular death, based on the SELECT trial. This indication can unlock coverage pathways that weight management alone cannot, including Medicare Part D, which now covers at least one anti-obesity medication under the Treat and Reduce Obesity Act effective April 2026.

Is there an oral version of Wegovy? Yes, approved December 2025 and available since January 2026. The OASIS 4 trial showed 16.6% mean weight loss at 64 weeks among adherent participants. Self-pay pricing starts at $149/month through NovoCare. If your injectable Wegovy was denied, the oral form may face different coverage criteria, so it's worth exploring both.

What if my plan won't cover any weight loss drugs? Wegovy's multi-indication label creates workarounds. The cardiovascular risk reduction indication, the MASH indication, and direct employer conversations are all viable pathways. See the Blanket Plan Exclusion section above for specifics.

How long do I have to file an appeal? Deadlines vary by insurer and are listed in your denial letter. Most commercial plans allow 180 days, but UnitedHealthcare allows just 65 days for many plan types, and Medicare Advantage allows 60 days. Regardless of how much time you have, moving quickly is always the better strategy.

What's the difference between Wegovy and Zepbound? Different drugs with different mechanisms. Wegovy (semaglutide) targets the GLP-1 receptor. Zepbound (tirzepatide) targets both GIP and GLP-1 receptors. Wegovy has cardiovascular risk reduction and MASH indications that Zepbound does not. CVS Caremark prefers Wegovy on its formularies; other PBMs may prefer Zepbound. Your appeal should be built around the specific drug your doctor prescribed and the clinical reasoning behind that choice.

Is it worth appealing? Almost always, yes. Fewer than 1% of denials are ever challenged, and insurers have built their entire denial infrastructure around that number. Appeals exist because the initial decision is frequently wrong, incomplete, or based on criteria the insurer misapplied. If your doctor prescribed Wegovy, there's a clinical reason, and the appeal gives you the chance to put that reasoning, backed by evidence, legal protections, and your own story, in front of someone who has to actually evaluate it.

Claimable's physician-led team has recovered over $30 million in care value for patients facing insurance denials. We're SOC 2 Type II certified and HIPAA compliant. Learn more about how we work →

If you landed here, chances are you just got an insurance denial for a treatment you need — and when you came to Claimable for help, we told you we don't support your medication or condition yet.

We know how frustrating that is. You're already dealing with the stress of being denied care your doctor prescribed, and the system is putting up roadblocks at every turn. While we're sorry we can't help you today, we're still here to help break those barriers down.

In this post, we'll explain why we aren't available for every denial just yet – but more importantly, what you can still do to fight for the coverage you deserve.

Why We Don't Support Everything (Yet)

Every condition and medication on the Claimable platform has a fully validated appeal strategy behind it. Our team researches and pressure-tests specific clinical guidelines, laws, insurer policy language, and denial patterns, building them into the platform before we'll generate a single appeal for a patient. That research is what allows us to create strong, powerful appeals from millions of possible strategy combinations rather than producing a generic letter.

We take seriously that what we create could determine whether or not you get treatment. An appeal built on the wrong argument, a misapplied citation, or a legal standard that doesn't apply to your plan type can mean another denial. When winning an appeal can mean the difference between getting care and going without it, it's critical to us to make sure every appeal we support meets a high bar for accuracy and quality.

So we don't support everything – just yet. We're always adding support for more medications and conditions, and our hope is that someday soon, Claimable can be used to appeal every single denial in the American healthcare system (all 850 million of them!). But until that day comes, we're still here to help you get covered however we can.

What Makes a Strong Appeal

Whether you use Claimable, write your own appeal, or use another tool, the strongest appeals combine three things: your personal health story (how the denial is specifically affecting your life and function), clinical evidence (guidelines and studies from recognized medical societies that support your treatment), and policy and legal analysis (the specific plan provisions and laws that apply to your denial type and plan type). When all three work together, that's when denials are most likely to be overturned.

The specifics matter more than most people realize. A formulary exclusion denial and a medical necessity denial for the same medication require fundamentally different strategies: different clinical evidence, different legal arguments, even a different tone. A formulary appeal needs to demonstrate that no therapeutically equivalent alternative exists for you specifically, while a medical necessity appeal needs to dismantle the insurer's rationale for why your treatment isn't needed. The legal protections available to you depend on your plan type and state.

The TLDR? Getting it right is important. That's what we're built to do, and in the meantime, we've put together some resources to help.

What Can I Do Instead of Claimable?

The good news: you have the right to appeal regardless of whether Claimable supports your condition. That right comes with real protections most patients don't know about — mandated response timelines, multiple levels of review, and for most plan types, the right to an independent external review where someone outside your insurance company evaluates your case.

Here's where to start:

Download Our Sample Appeal Letter Template → Follows the three-pillar structure with prompts for your personal details, clinical evidence, and legal arguments.‍

10 Essential Patient Appeal Rights Every Patient Should Know →
Breaks down the specific legal protections you have when appealing a denial — including rights most patients don't know exist.

How to Get a Non-Formulary Drug Covered →
If your denial is formulary-related, this guide walks you through the exception request and appeal process step by step.

Why You Should Appeal Your Insurance Denial Yourself →
Patient appeals carry legal protections that provider appeals don't. This post explains why — and how to use that to your advantage.

Find Your State Department of Insurance →
Every state has one, and they exist to help people in your situation. They can tell you your exact review rights and intervene if your insurer isn't following the rules.

ProPublica's Claim File Helper →
Free tool that generates a letter requesting your claim file — the internal notes, correspondence, and records your insurer used when deciding to deny you.

HealthInsuranceAppeals.org →
Led by attorney D. Brian Hufford, this organization partners with law schools to provide free pro bono assistance to patients appealing health insurance denials.

Patient Advocate Foundation →
Offers case management for patients navigating insurance denials.

Ask your doctor's office about submitting a peer-to-peer review request or letter of medical necessity alongside your appeal. A patient appeal and a provider appeal working in parallel create pressure from two directions – and if one is denied, the other keeps going.

Thinking About Using ChatGPT or Another AI Tool?

We say: go for it. Using an AI tool to draft your appeal is far better than not appealing at all. But don't treat its output as final – AI language models make mistakes that aren't always obvious, and in an appeal, accuracy matters. This applies to general-purpose AI like ChatGPT and Gemini, as well as many broad insurance AI tools that build appeals off of general statements instead of specific medical information. Before you submit anything AI-generated:

Check that every clinical study cited actually exists. Search each one by title in PubMed or Google Scholar. AI tools routinely fabricate convincing-looking citations that aren't real, and a fabricated citation undermines your credibility with the reviewer.

Confirm that laws and regulations referenced are real and apply to your plan type. AI tools will cite statutes that don't exist or apply federal protections to plans they don't cover. Look up anything the tool references.

Make sure the appeal addresses your actual denial reason. Medical necessity, formulary exclusion, and step therapy denials each require fundamentally different arguments. If the tool argues the wrong one, the strongest evidence in the world won't matter.

Verify that clinical guidelines are current and from recognized medical societies. Outdated guidelines can work against you if the reviewer is using the current version.

Be careful with your personal health information.Your appeal will include sensitive medical details — your diagnosis, treatment history, medications, and how your condition affects your daily life. Before entering any of that into an AI tool, understand how that tool handles your data. Most general-purpose AI chatbots are not HIPAA-compliant, which means your health information may be stored, used for model training, or accessible in ways you didn't intend.

You might be thinking… isn't Claimable powered by AI? The difference is that our AI is purpose-built for insurance appeals. We use a human-in-the-loop model and multiple quality check gates that cross-reference our database for accuracy, strategy alignment, and argument soundness. Plus, we're HIPAA-certified and SOC 2 compliant: Your data is fully encrypted and handled under the same privacy standards your doctor's office is required to follow.

We're Adding Support for More Appeals All the Time

Our team is continually researching and validating appeal strategies for new conditions and medications. The 85+ medications we support today are growing – and our goal is to be there for every patient who needs to appeal a denial, no matter what treatment they've been denied.

If you'd like to be notified when we add support for your condition, sign up updates here. We'll let you know the moment we can help.

In the meantime: you have the right to appeal. The process is stacked against you on purpose — insurance companies count on the complexity being enough to make you walk away. Nearly half of patients do. But the ones who appeal, with the right evidence and the right arguments, overturn denials at dramatically higher rates than most people expect.

Your denial isn't the final answer. It's the first move in a process that's designed to have a next step. Take it.

Over 70% of patients referred to Claimable complete and submit an appeal, with more than 80% submitted same day

SAN FRANCISCO — Claimable today announced the debut of its enterprise patient access platform, purpose-built for pharmaceutical manufacturers, health systems, and access partners, including specialty pharmacies and patient support hubs.

The AI-powered platform extends patient access programs beyond prior authorization, automating the appeal layer that sits between a patient's prescription and coverage for their needed therapy. By integrating directly into existing patient support programs and revenue cycle operations, Claimable addresses the growing denial problem without adding headcount or replacing existing systems.

The Denial Crisis

Denials are now the leading cause of treatment delays and patient dropout in specialty care. Denial rates are rising 25% year over year as payers increasingly leverage AI to automate claim reviews. The support infrastructure most manufacturers and health systems rely on was built for a different era. Call centers, manual workflows, overstretched clinical staff, disconnected case management: none of it was designed to keep pace with AI-powered denials. As a result, 99% of denials are never challenged, and 46% of patients abandon treatment after a denial, leaving medically necessary therapies out of reach for millions.

Platform Scale and Results

Claimable covers more than 85 commonly restricted treatments spanning asthma, obesity, diabetes, autoimmune disorders, and rare pediatric diseases. The enterprise platform is already live across 10 programs supporting treatments used by over one million patients nationwide, where initial denial rates can reach 70%.

"Insurers have figured out how to use AI to deny care at scale, while everyone else is left trying to fight back one appeal at a time," said Warris Bokhari, MD, CEO and Co-Founder of Claimable. "The asymmetry is stark — denials are automated, but appeals are not, and that breakdown puts lives at stake. Patients are left to make impossible choices: delay treatment, pay out of pocket for medications that can cost more than $1,000 per month — or walk away from care altogether. We built Claimable to restore that balance of power, using AI so appeals move as fast as denials do, at the scale the problem demands."

Most denied patients receive no appeal support at all, and those who do wait days or weeks for a provider to prepare and file. By contrast, Claimable scales appeal support to every denied patient, cutting the time between denial and treatment initiation. More than 70% of patients referred to Claimable complete and submit an appeal, with more than 80% submitted the same day.

Across established conditions, Claimable has achieved success rates exceeding 80%, with denials overturned in under 10 days on average. To date, the platform has recovered more than $30 million in previously denied care, reducing treatment delays, improving patient retention, and saving access and clinical teams hours of administrative work per appeal.

How It Works

The process begins with flexible intake, allowing patients to enter through direct links, support team referrals, or API-based integrations with existing workflows. A guided, self-service experience allows most patients to build a personalized appeal in under 30 minutes.

Claimable's AI appeal engine generates a case-specific appeal by combining three layers of evidence: the patient's personal health narrative, a curated library of clinical studies and guidelines, and laws and health plan policies. Each appeal is matched to the exact treatment, condition, insurer, and denial reason, producing millions of bespoke strategy combinations.

Enterprise Capabilities

The platform also provides enterprise teams with a set of operational tools to support patients throughout the appeals process:

Enterprise operations console: centralized management layer supporting referral submission, document upload, real-time case tracking, and outcome visibility with role-based access controls.

Program dashboard: aggregate, de-identified reporting to continuously optimize access strategies, including denial patterns and outcomes, conversion, and engagement analytics.

Access content suite: branded landing pages, advocacy resources, training guides, call scripts, and email templates, all built to medical-legal review and compliance standards.

Security and Compliance

Security, governance, and safety oversight are native to the platform, including HIPAA-compliant hosting, SOC 2 Type II certification, consent management, audit trails, and AI-powered pharmacovigilance workflows that monitor patient-reported responses against FDA adverse event data.

Each enterprise deployment is assigned a named appeal specialist available to review escalated cases and adjust appeal approaches as payer behavior changes.

To learn more about how Claimable supports pharmaceutical manufacturers and health systems, visit getclaimable.com/for-pharma and getclaimable.com/for-health-systems.

About Claimable

Claimable is an intelligent patient access platform that closes the gap between the care patients are prescribed and the coverage they receive by challenging insurance denials at scale. Leveraging purpose-built AI and automation, the platform analyzes clinical research, policy details, appeals data, and patients' unique medical histories to generate and submit customized appeals in minutes. Available nationwide, the platform supports denials from all insurance providers, including Medicare and Medicaid. Claimable has been recognized by Fierce Healthcare's Fierce 15, Fast Company's World Changing Ideas, and TIME100 Health for its leadership in patient access innovation. Backed by Quiet Capital, Next Level Ventures, Walkabout VC, Great Oaks, and others, the company continues to push the boundaries of AI innovation in healthcare. To learn more, visit www.getclaimable.com.

Contact:
Emily Fox
press@getclaimable.com

Your neurologist prescribed Emgality because it’s the right preventive treatment for your migraines. Your health insurer decided otherwise. But an insurance denial isn’t the end of the conversation, and you have legal rights that most patients never exercise.

Emgality (galcanezumab-gnlm) is a calcitonin gene-related peptide (CGRP) monoclonal antibody, one of a class of injectable therapies specifically designed to prevent migraine attacks before they start. Unlike older preventive medications that were originally developed for other conditions and repurposed for migraines, Emgality was built from the ground up to target the CGRP pathway, a biological mechanism central to how migraines work. It received FDA approval in September 2018 for preventive treatment of migraine in adults and is also approved for episodic cluster headache.

Despite strong clinical evidence and more than 90% of commercial health plans including Emgality coverage on their formularies, actually getting that coverage activated is a different story. Most plans require prior authorization, and the majority demand that you try and fail two or more older preventive medications before they’ll approve a CGRP drug like Emgality. If you’re reading this, you’ve likely already hit that wall.

Here’s the reality insurance companies don’t advertise: fewer than 1% of denied claims are ever appealed. When patients do appeal with the right evidence, the results are dramatically different. At Claimable, over 80% of our appeals succeed in established conditions.

This guide explains exactly why Emgality gets denied, what makes these denials often medically unjustifiable, and how to build an appeal that wins, including the clinical arguments, documentation strategies, and legal protections that actually change outcomes.

Why Insurance Companies Deny Emgality Coverage

Before you do anything else, find the specific reason your insurer denied your prescription. The denial reason determines your entire appeal strategy, and using the wrong argument wastes time you don’t have.

The Step Therapy Problem: Months of Medication Roulette Before You Get What Actually Works

Most Emgality denials come down to one thing: step therapy. Your health insurer requires you to try and fail older, cheaper standard preventatives before they’ll approve a migraine-specific CGRP inhibitor, even when the leading medical society in headache medicine says that requirement is no longer clinically justified.

The medications insurers typically demand you try first weren’t designed for migraines at all. They’re repurposed therapies from other fields: beta-blockers originally developed for blood pressure and heart conditions (propranolol, metoprolol), antidepressants (amitriptyline, venlafaxine), and antiepileptic drugs (topiramate, valproate). Some of these drugs do help some patients, but the side effect profiles are significant, and the dropout rates tell the real story.

Consider topiramate, one of the most commonly required step therapy medications. In clinical trials for migraine prevention, approximately 25% of patients on the standard 100mg dose discontinued treatment due to adverse events. The most common reasons: paresthesia (tingling and numbness), fatigue, and difficulty with concentration and memory. These side effects are severe enough that patients often call topiramate “Dopamax” for its cognitive effects. Beta-blockers can cause fatigue, depression, and exercise intolerance. Antidepressants carry their own constellation of side effects including weight gain, dry mouth, and sedation.

Insurers know all of this. Step therapy isn’t a medical strategy. It’s a cost strategy. The older drugs are cheaper, and the insurer saves money for every month you spend trying medications that may not work and may make you feel worse.

The American Headache Society’s 2024 position statement directly challenges this approach. After reviewing more than a decade of clinical evidence and real-world experience, the AHS now recommends that CGRP inhibitors, including Emgality, should be considered a first-line option for effective migraine prevention, without requiring prior failure of other drug classes. The statement is unequivocal: the cumulative evidence for efficacy, safety, and tolerability of CGRP therapies is significantly greater than that for any established migraine preventive treatment.

When your insurer requires you to spend months cycling through medications with high discontinuation rates and substantial side effects before approving Emgality, they’re overriding the judgment of both your prescribing neurologist and the nation’s leading headache specialists.

The Most Common Emgality Denial Types

Step Therapy Required

This is the most common reason Emgality injections are denied. Insurers including Aetna, Anthem Blue Cross, Cigna, UnitedHealthcare, Blue Shield, and Humana all typically require documented failure of at least two classes of preventive medications before approving CGRP drugs. The specific requirements vary by plan, but the pattern is consistent: try the cheap options first, even if your doctor has already determined they’re not right for you.

“Failure” is defined more broadly than most patients realize, and that’s where your appeal leverage lives. You don’t need to prove a medication was completely useless. Any of the following counts: the drug didn’t reduce your migraine frequency enough, side effects or intolerances made the drug unbearable, you have a medical condition that contraindicates the drug (cardiovascular disease for beta-blockers, kidney stones for topiramate, pregnancy planning for valproate), or you had to discontinue for any documented medical reason. Prior medication trials from other doctors or previous insurers also count. You shouldn’t have to restart the failure clock every time your coverage changes.

Important: The AHS 2024 position statement specifically states that initiation of CGRP-targeting therapies should not require trial and failure of non-specific migraine preventive medication approaches. This is your strongest clinical argument in any step therapy appeal.

Not Medically Necessary

A medical necessity denial usually means the initial submission didn’t include enough clinical detail, not that your insurer made a careful medical judgment. Common documentation gaps for Emgality include: not specifying the number of migraine days per month, not providing a complete treatment history with specific drug names, dosages, durations, and outcomes, not documenting how migraines impact your ability to work and function, or not explaining why Emgality specifically is the right choice.

For Emgality, your prescriber’s documentation should establish your migraine diagnosis with the correct ICD-10 code, quantify your migraine burden (frequency, severity, and disability), list every prior preventive medication tried with specific reasons each was inadequate, and articulate the clinical rationale for choosing a CGRP monoclonal antibody.

Not on Formulary / Non-Preferred Brand

Some health insurance plans prefer a different injectable CGRP medication, often Aimovig (erenumab), Ajovy (fremanezumab), or Vyepti (eptinezumab), over Emgality. This is typically a pricing decision, not a clinical one. All four injectable CGRP drugs are effective preventive therapies, but they’re not interchangeable for every patient.

This matters for your appeal: Emgality and Ajovy work by binding the CGRP ligand (the protein itself), while Aimovig targets the CGRP receptor. These are meaningfully different mechanisms, and patients who don’t respond to one may respond well to another. If your insurer is asking you to switch to a preferred alternative, and you’ve already tried that medication without adequate results or your neurologist has a specific clinical reason for choosing Emgality, that’s a strong basis for a formulary exception.

The CONQUER trial specifically demonstrated that Emgality is effective in patients who have failed two to four prior preventive medication categories, meaning it has published evidence of working in exactly the population most likely to face insurance barriers.

Frequency Threshold Not Met

Most insurers require a minimum of 4 migraine days per month to qualify for Emgality coverage. If your denial cites this reason, it often means the documentation didn’t clearly establish your migraine frequency, not that you don’t actually meet the threshold. A detailed headache diary showing your true migraine burden, corroborated by your neurologist’s clinical assessment, is typically what’s needed to address this.

Keep in mind that many patients underreport migraine frequency in routine visits. If you experience 4 or more migraine days per month (the standard clinical threshold for considering preventive treatment), make sure that number is explicitly documented in your medical records.

Incorrect Diagnosis Code

Emgality coverage requires specific ICD-10 migraine diagnosis codes. Common codes that support Emgality prescriptions include: migraine without aura (G43.00, G43.01), migraine with aura (G43.10, G43.11), chronic migraine without aura (G43.709, G43.711), and migraine, unspecified (G43.90, G43.91). Using a general headache code like R51.9 (“headache, unspecified”) will almost certainly trigger a denial.

If your denial stems from a coding issue, this is often the simplest fix. Work with your prescriber’s office to verify and correct the submitted diagnosis code.

Prior Authorization Expired

Emgality typically requires reauthorization every 6 to 12 months. If your PA has lapsed, you’ll need to resubmit with updated documentation showing that the medication is still working, ideally including migraine diary data demonstrating continued response (a 50% or greater reduction in monthly migraine days is the standard clinical benchmark). Start the renewal process 30 to 45 days before your current authorization expires to avoid gaps in treatment.

How to Appeal an Emgality Denial: Step by Step

A denial is not a final answer. It’s the beginning of a process that patients are legally entitled to, and that works far more often than the insurance industry would like you to believe.

Step 1: Read Your Denial Letter Carefully

Your denial letter must include the specific reason for the denial, your appeal rights, and the deadline to file. Find the deadline immediately. Most commercial plans allow 180 days, but some insurers set shorter windows. UnitedHealthcare allows 65 days. Medicare Advantage plans follow CMS guidelines of 60 days. Missing your deadline forfeits your right to appeal.

Step 2: Understand That You Can Appeal Independently

You can file a patient-initiated appeal separate from anything your doctor’s office submits. This isn’t just a backup. Patient appeals carry their own legal protections under the ACA, including mandated response timelines, the right to escalate to an independent external reviewer, and multiple levels of appeal. If your neurologist’s prior authorization was denied, your path is still open.

Step 3: Verify Clinical Details With Your Prescriber

Before building your appeal, confirm with your doctor’s office: Is your migraine frequency clearly documented? Are all prior preventive medication trials listed with specific drugs, dosages, durations, and reasons for discontinuation? Is the correct ICD-10 diagnosis code on file? Was the Emgality prescription written for the correct loading and maintenance dose? If the denial stems from a documentation gap, a corrected PA resubmission may resolve it without a formal appeal.

Step 4: Get a Letter of Medical Necessity

This is the most important document in your appeal. For Emgality, a strong letter of medical necessity from your prescribing neurologist or headache specialist should include your migraine diagnosis and monthly frequency, a detailed history of every prior preventive medication tried (names, doses, duration of each trial, and specific reason each was discontinued, whether for side effects, lack of efficacy, or contraindications), how migraines affect your ability to work, care for your family, and function in daily life, and the clinical rationale for choosing Emgality, including references to the AHS guidelines supporting CGRP therapies as first-line prevention.

How to ask: “My insurance denied Emgality. Would you write a letter of medical necessity for my appeal? I can bring a list of every preventive I’ve tried and what happened with each one.” Specificity wins appeals. Vague statements like “patient failed prior therapies” are far less effective than naming the exact drugs, doses, and outcomes. If your primary care provider submitted the original prescription, consider asking a neurologist or headache specialist to write the appeal letter. Clinicians with specialized headache expertise carry additional weight with insurance medical directors.

Step 5: Build Your Appeal Package

A complete appeal should include a cover letter summarizing your case, the letter of medical necessity from your prescriber, supporting clinical documentation (office notes, headache diary data, treatment history), and a personal statement about how the denial affects your health and life.

The three pillars of a winning appeal:

Your story — How migraines disrupt your daily life. Missed work days, canceled plans, emergency room visits, the toll on your family. This isn’t supplemental. It provides the human weight that clinical data alone can’t communicate.

Clinical evidence — Peer-reviewed studies including the EVOLVE-1 and EVOLVE-2 trial results showing significant reductions in monthly migraine days vs. placebo, the AHS 2024 position statement supporting CGRP therapies as first-line, and any published evidence specific to your situation (the CONQUER trial is especially relevant if you’ve failed multiple prior preventives).

Policy and legal analysis — How your situation meets your plan’s own coverage criteria, applicable state laws, and federal protections under the ACA for appeals and external review.

Step 6: Submit and Track

Follow your denial letter’s submission instructions precisely. Your insurer must respond within 30 days for standard appeals or 72 hours for an expedited appeal (also called an urgent appeal; request this if a delay in treatment could seriously harm your health). Keep records of everything: submission date, method (fax, mail, portal), and all confirmation numbers.

Step 7: Escalate If Needed

If your internal appeal is denied, you have the right to an external review by an independent third party who doesn’t work for your health insurer. External reviewers evaluate medical justification, not the insurer’s financial preferences. These reviews overturn denials more often than most patients expect, because the standard shifts from the insurer’s internal criteria to independent clinical judgment.

The system is designed to wear you down. Persistence is part of the strategy.

An Easier Path: Let Claimable Handle Your Emgality Appeal

If building an appeal from scratch isn’t realistic, or if you’ve already been denied and don’t have the bandwidth for another round, Claimable can handle it for you.

Here’s how it works:

Answer a few questions about your Emgality denial and medical history. We build your case using our database of 4+ million clinical studies, insurer policies, and legal standards. We create a fully customized appeal with your personal story, clinical evidence, and policy analysis. We submit it for you, faxed and mailed directly to your insurer. We guide you through escalation if needed.

Over 80% of Claimable appeals succeed, with most resolved in 10 days or less.

“When my insurance company denied my claim to continue with my medicine, I felt defeated at first… Then I found Claimable. In the end I ended up winning my claim and I couldn’t have done it without Claimable. I highly recommend them.” — April A.

Appealing with Claimable costs $39.95. No success fees, no hidden costs, just a flat fee. When Emgality runs $700 to $970 per month without insurance coverage, the math is straightforward.

Start your Emgality appeal →

Appeal Timelines: How Long Does an Emgality Appeal Take?

A complete, well-documented appeal submitted from the start is the fastest path to a decision. The average Claimable appeal gets a response in just 10 days.

FAQs

Why was my Emgality denied if my plan covers it?

Having Emgality on your plan’s formulary doesn’t guarantee automatic approval. Most plans require prior authorization, and those PA criteria typically include step therapy (proof that you’ve tried and failed older preventive medications), minimum migraine frequency thresholds, and specific documentation requirements. Your plan may technically cover Emgality, but “covered” and “approved without a fight” are very different things.

Do I really have to try older medications like topiramate before getting Emgality?

That depends on your insurer’s current policies, but you may not need to start from scratch. If you’ve previously tried and discontinued standard preventatives for any documented medical reason (side effects, intolerances, lack of efficacy, or contraindications) those prior trials should satisfy step therapy requirements. And if your healthcare provider can cite the AHS 2024 position statement recommending CGRP inhibitors as first-line, that strengthens the argument that step therapy shouldn’t apply to your case at all.

Can I appeal an Emgality denial myself, or does my doctor have to do it?

You can appeal yourself. Patient-initiated appeals carry their own legal protections: mandated timelines, the right to external review, and multiple appeal levels. Your appeal is independent of anything your doctor files. Both can proceed simultaneously.

What’s the difference between Emgality and other CGRP injections like Aimovig?

All four injectable CGRP drugs, Emgality, Aimovig (erenumab), Ajovy (fremanezumab), and Vyepti (eptinezumab), are effective preventive therapies for migraines, but they work through slightly different mechanisms. Emgality and Ajovy target the CGRP protein itself (the ligand), while Aimovig blocks the CGRP receptor. Oral CGRP options also exist: Qulipta (atogepant) for prevention and Nurtec (rimegepant) for both prevention and acute treatment. But the injectable monoclonal antibodies offer a different pharmacological approach with once-monthly dosing. The key point: patients who don’t respond adequately to one CGRP medication may respond well to another. Failing on one doesn’t mean the entire class won’t work for you. Your doctor chose Emgality for a reason specific to your clinical situation.

How does the Emgality injection work?

Emgality is a once-monthly injection that you self-administer at home using a prefilled pen or syringe. The first dose is a loading dose of 240mg (two 120mg injections), followed by 120mg once monthly. In clinical trials, patients treated with Emgality experienced approximately 4.7 fewer migraine headache days per month compared to 2.8 fewer days with placebo, with 50% responder rates of approximately 60% over 6 months of treatment. That means about 6 in 10 patients saw their migraine days cut in half or more.

How much does Emgality cost without insurance?

Without insurance or discounts, Emgality costs approximately $700 to $970 per month for the maintenance dose (one 120mg prefilled pen). The first month’s loading dose requires two pens, roughly doubling the initial cost. Eli Lilly offers the Emgality Savings Card for commercially insured patients, which can reduce the monthly cost to as little as $35 (up to $4,900 in annual savings). Patients without commercial insurance may qualify for the Lilly Cares Foundation Patient Assistance Program, which provides Emgality at no cost to qualifying individuals. Note that neither the savings card nor the patient assistance program is available to patients enrolled in Medicare, Medicaid, or other government-funded programs, but Medicaid plans in many states do cover Emgality with copays as low as $4 to $9 per month.

What if my insurer wants me to switch to a different CGRP medication?

If your plan prefers Aimovig, Ajovy, or Vyepti over Emgality, your appeal should explain why your neurologist specifically chose Emgality. Strong grounds for a formulary exception include: you’ve previously tried the preferred alternative without adequate results, the preferred drug is contraindicated for you, or there’s a specific clinical rationale (such as Emgality’s mechanism of targeting the CGRP ligand vs. the receptor). The CONQUER trial demonstrated Emgality’s efficacy specifically in patients who had failed multiple prior preventive categories, evidence that strengthens your case if you’ve been through this before.

Is it worth appealing an Emgality denial?

Yes. The insurance industry relies on patients accepting denials without challenge. Fewer than 1% ever appeal. But denials are frequently the result of incomplete documentation, misapplied criteria, or step therapy requirements that contradict current medical guidelines. Your neurologist prescribed Emgality because your migraines are serious enough to warrant targeted preventive treatment. The appeal is your chance to make that case with the right evidence and legal framework behind you.

Claimable’s physician-led team has helped patients recover millions in care access by fighting insurance denials. We’re SOC 2 Type II certified and HIPAA compliant. Learn more about how Claimable works →

Related: Insurance Denied Ubrelvy? How to Appeal and Get Covered

Related: Insurance Denied Nurtec? Here’s What to Do

Your doctor prescribed Ubrelvy because it's the right acute treatment for your migraines — and in many cases, because triptans aren't safe or effective for you. Your insurer disagreed. But a denial letter isn't the final word, and you have more power to challenge it than you probably realize.

Ubrelvy (ubrogepant) was the first oral calcitonin gene-related peptide (CGRP) medication FDA-approved specifically for treating migraine attacks. It works through an entirely different mechanism than triptans — blocking the CGRP protein involved in migraine pain, nausea, and sensitivity to light and sound, rather than constricting blood vessels. That distinction matters clinically, and it matters enormously when it comes to insurance coverage, because the very reason your doctor chose Ubrelvy is often the reason your insurer tries to deny it.

Here's what AbbVie's own access data shows: 56% of commercially insured patients are unrestricted or need only minimal prior therapy to access Ubrelvy. That means nearly half face significant coverage hurdles — prior authorization requirements, step therapy demands, or outright denials. If you're reading this, you're likely in that group.

The good news: denials can be overturned. Fewer than 1% of denied claims are ever appealed, and insurance companies bank on that silence. But when patients appeal with the right evidence and strategy, the results are dramatically different. At Claimable, over 80% of our appeals succeed in established conditions.

This guide breaks down exactly why Ubrelvy gets denied, how to identify your specific situation, and what a winning appeal looks like — including the clinical arguments, legal protections, and documentation strategies that actually move the needle.

Why Insurance Companies Deny Ubrelvy

The single most important thing to do before anything else: understand the specific reason your insurer denied coverage. The denial reason shapes your entire appeal strategy. Getting it wrong means building a case that doesn't address the actual barrier.

The Triptan Paradox: Why Ubrelvy Denials Are Often Medically Absurd

Here's the central irony of most Ubrelvy denials: your doctor likely prescribed Ubrelvy because triptans don't work for you, cause intolerable side effects, or are medically unsafe given your health history. And your insurer's most likely response is to demand that you try more triptans first.

This isn't a minor bureaucratic inconvenience. Research published in the Journal of Primary Care & Community Health found that more than 20% of commercially insured migraine patients have a cardiovascular condition that specifically contraindicates triptan use — conditions like coronary artery disease, peripheral vascular disease, uncontrolled hypertension, or history of stroke. An additional 25% have multiple cardiovascular risk factors that carry formal warnings and precautions against triptan use. That's nearly half of all migraine patients for whom triptans are either unsafe or require serious caution.

Triptans work by constricting blood vessels. That vasoconstriction is the source of both their efficacy and their risk. Ubrelvy doesn't constrict blood vessels at all — it targets the CGRP receptor, addressing migraine pain through an entirely different pathway. For patients with cardiovascular concerns, this isn't a preference. It's a medical necessity.

When an insurer requires you to try and fail triptans before approving Ubrelvy, and your medical history includes cardiovascular contraindications, they're effectively asking you to take medications your own doctor has determined could put your health at risk. That's a powerful foundation for an appeal.

Even for patients without cardiovascular issues, there are legitimate clinical reasons triptans may not be appropriate: intolerable side effects (chest tightness, tingling, fatigue), medication interactions, or simply inadequate relief. Roughly one-third of migraine patients don't respond well to triptans or can't tolerate them. Ubrelvy was developed precisely for this population.

The Most Common Ubrelvy Denial Types

Every denial letter uses insurer language designed to sound definitive. Understanding what each denial type actually means — and where the insurer's reasoning is weakest — is how you build a targeted appeal.

Step Therapy Required

This is the most frequent reason Ubrelvy is denied. Major insurers including Anthem Blue Cross, Aetna, Blue Shield, and UnitedHealthcare all typically require prior authorization for Ubrelvy, and most mandate documented failure of at least two triptans before they'll approve a gepant for acute migraine treatment. Some plans require even more — failure of triptans plus NSAIDs, or failure of specific named triptans (sumatriptan, rizatriptan) rather than the class broadly. Specific step therapy requirements vary by plan and even by state, so check your denial letter for the exact criteria your insurer applied.

The critical detail most patients miss: "failure" has a broad medical definition that works in your favor. You don't have to prove a triptan was completely ineffective. Side effects count. Contraindications count. Medical reasons a drug is inappropriate for you — cardiovascular disease, medication interactions, hemiplegic migraine — all qualify as failure. If your doctor determined triptans aren't safe for you, that is a documented failure, even if you never took a single dose.

The American Headache Society's 2021 consensus statement specifically recommends gepants like Ubrelvy for patients who have failed, cannot tolerate, or have contraindications to triptans. And the AHS's 2024 position statement goes further, establishing CGRP-targeting therapies as a first-line option for migraine treatment without requiring prior failure of older drug classes. When your insurer demands triptan trials that your doctor has already ruled out, they're contradicting the leading medical society in headache medicine.

Not Medically Necessary

This denial usually means the paperwork was too thin — not that someone carefully reviewed your history and concluded Ubrelvy isn't appropriate. The most common gaps: not specifying migraine frequency and severity, not listing prior treatments tried and why they failed, not documenting impact on daily functioning, or not explaining why Ubrelvy specifically is the right choice over other acute options.

For Ubrelvy, your prescriber's documentation should make clear why a non-vasoconstrictive acute treatment is needed. If you have cardiovascular risk factors, those need to be spelled out explicitly. If you tried triptans and experienced side effects, those side effects need to be named and described, not just referenced in passing.

Quantity Limit Exceeded

Insurer quantity limits for Ubrelvy vary more than you might expect. Some plans cap coverage at 8 tablets per month, others at 10, and some allow up to 16 (which is what AbbVie packages as a standard prescription). Ubrelvy's prescribing information notes that treating more than 8 migraines in a 30-day period hasn't been studied for safety — but that's 8 migraines, not 8 tablets. Since patients can take a second dose 2 hours after the first if needed, someone treating 4–5 migraines per month with an optional second dose may legitimately need more than 8 tablets.

If your insurer denied based on quantity, your prescriber should submit documentation confirming the clinical rationale for the prescribed amount — including migraine frequency, whether a second dose is typically needed, and why the quantity is medically appropriate.

Not on Formulary / Non-Preferred Brand

Some plans position Nurtec as their preferred CGRP medication over Ubrelvy, since Nurtec carries both acute and preventive indications. Others prefer neither and want you on triptans entirely. If your plan prefers a different medication, the appeal needs to explain why Ubrelvy specifically is the right choice for your situation.

Strong arguments for a formulary exception include: you've already tried and failed the preferred alternative, the preferred drug is contraindicated for you, or there are specific clinical reasons Ubrelvy is more appropriate. If your prescriber chose Ubrelvy because you need acute-only treatment and the other options haven't worked or aren't suitable, that rationale needs to be documented clearly.

Dose-Level Denial (50mg vs. 100mg)

Some insurers will approve Ubrelvy at the 50mg dose but deny the 100mg. Both doses showed similar rates of pain freedom in the ACHIEVE trials — 21% at 2 hours for both 50mg and 100mg — but the 100mg dose was the one studied in the landmark PRODROME trial and is often the dose prescribed for patients with more severe or harder-to-treat migraines. Dose modifications are also required for patients on certain medications, which can affect which strength is clinically appropriate.

If your insurer denied the 100mg dose, your prescriber should provide a clinical rationale: why the higher dose is needed, whether the 50mg was tried and found insufficient, or whether dose adjustments related to other medications require the 100mg formulation.

Duplicate CGRP Therapy Denial

If you're already taking an injectable CGRP medication for prevention — Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), or Vyepti (eptinezumab) — some insurers will deny Ubrelvy on the grounds that you can't use two CGRP-targeting drugs at the same time.

This denial is frequently wrong. Ubrelvy (an oral CGRP receptor antagonist for acute use) and injectable CGRP monoclonal antibodies (for prevention) work through different mechanisms and serve different clinical purposes. Published research in Advances in Therapy (Blumenfeld et al., 2022) specifically evaluated the safety and efficacy of ubrogepant in patients taking concomitant preventive CGRP monoclonal antibodies — and found no negative impact on either safety or efficacy. The Ubrelvy prescribing information itself notes that patients in clinical trials were able to use concomitant preventive medications.

A detailed clinical rationale from your neurologist or headache specialist explaining the different mechanisms, distinct indications, and published evidence supporting combination use is typically what's needed to overturn this type of denial.

Incorrect Diagnosis Code

Like all migraine medications, Ubrelvy coverage can hinge on whether the right ICD-10 code was submitted. Using a general headache code (like R51.9 for "headache, unspecified") instead of a specific migraine code will often trigger an automatic denial. The most common migraine diagnosis codes that support Ubrelvy coverage include: migraine without aura (G43.00, G43.01), migraine with aura (G43.10, G43.11), migraine unspecified (G43.90, G43.91), and chronic migraine (G43.709, G43.711).

If your denial seems to stem from a coding issue, this is usually the easiest fix — work with your prescriber's office to verify the correct code was submitted and resubmit if needed.

How to Appeal a Ubrelvy Denial: Step by Step

The insurance industry has conditioned patients to treat a denial as a final answer. It's not. Appeals are a legal right, and they work far more often than most people expect.

Step 1: Read Your Denial Letter Carefully

Every denial letter is legally required to include three things: the specific reason for denial, your appeal rights, and the deadline to file. Find the deadline first — it's the most time-sensitive detail. Most commercial plans give 180 days, but timelines vary by insurer. UnitedHealthcare allows just 65 days for most plan types. Medicare Advantage plans follow CMS guidelines of 60 days. Missing the deadline eliminates your right to appeal, so move quickly.

Step 2: Know That You Can File Your Own Appeal

Patient-initiated appeals are separate from (and in addition to) anything your doctor's office files. This is a distinction most people don't know about, and it matters. Patient appeals carry their own legal protections — mandated response timelines, the right to escalate to independent external review, and multiple levels of appeal. If your doctor's prior authorization was denied, that doesn't close the door for you. You have your own path.

Step 3: Confirm the Clinical Details With Your Prescriber

Before building your appeal, verify with your doctor's office: Was the correct migraine diagnosis code submitted? Were prior triptan trials (or contraindications to triptans) documented? Was the prescribed dose and quantity clearly justified? If the denial stems from a paperwork gap rather than a genuine coverage dispute, a corrected prior authorization resubmission may resolve the issue without a formal appeal.

Step 4: Get a Letter of Medical Necessity

A letter of medical necessity from your prescribing physician is the most important document in your appeal package. For Ubrelvy specifically, this letter should include your migraine diagnosis and frequency, a detailed history of prior treatments tried and outcomes (especially triptans — why they failed, caused side effects, or are contraindicated), any cardiovascular conditions or risk factors that make triptans unsafe, the specific clinical rationale for why Ubrelvy is the appropriate treatment, and the prescribed dose and quantity with medical justification.

How to ask: Be direct with your doctor. "My insurance denied Ubrelvy. Would you write a letter of medical necessity for my appeal? I can bring information on what the insurer typically requires." If your doctor's office isn't experienced with these, offering to share a template or outline can make a significant difference.

Step 5: Build Your Appeal Package

A complete appeal submission should include a cover letter summarizing your case, the letter of medical necessity from your prescriber, supporting clinical documentation (office visit notes showing migraine frequency, treatment history, cardiovascular history if relevant), and a personal statement explaining how the denial affects your health and daily life.

The three pillars of a winning appeal:

Your story — How migraines impact your daily life, your work, your relationships. How the denial has affected your ability to manage your condition. This isn't filler — it provides the human context that clinical data alone can't convey.

Clinical evidence — The ACHIEVE trial results, the AHS consensus statements, specific evidence supporting Ubrelvy for your situation. If cardiovascular contraindications to triptans are part of your case, the published research on triptan contraindication prevalence strengthens the argument that Ubrelvy isn't a luxury — it's a necessity.

Policy and legal analysis — How your situation meets coverage criteria under your specific plan, applicable state laws, and federal regulations like the ACA's protections for appeals and external review.

Step 6: Submit and Track

Follow the submission instructions in your denial letter exactly. Your insurer is required to respond within 30 days for standard appeals or 72 hours for urgent/expedited cases. Document everything: when you submitted, how (fax, mail, portal), and any confirmation numbers or reference IDs.

Step 7: Escalate If Needed

If your internal appeal is denied, you have the right to an external review by an independent third party who doesn't work for the insurer. External reviewers evaluate whether the denial was medically justified, not whether the insurer wants to pay. These reviews frequently overturn denials that make it to this stage, because the standard of review shifts from the insurer's internal criteria to objective clinical evidence.

Don't stop after the first "no." The appeals process exists because denials are often wrong. Persistence isn't just an emotional decision, it's a strategic one.

An Easier Path: Let Claimable Handle Your Ubrelvy Appeal

If the process above feels like a lot, or if you've already been through one round of denials and don't have the energy for another, Claimable can take it from here.

Here's how it works:

Answer a few questions about your Ubrelvy denial and medical history. We build your case using our database of 4+ million clinical studies, insurer policies, and legal standards. We create a fully customized appeal with your personal story, clinical evidence, and policy analysis. We submit it for you — faxed and mailed directly to your insurer. We guide you through escalation if needed.

Over 80% of Claimable appeals succeed, with most resolved in 10 days or less.

"When my insurance company denied my claim to continue with my medicine, I felt defeated at first… Then I found Claimable. In the end I ended up winning my claim and I couldn't have done it without Claimable. I highly recommend them." – April A.

Appealing with Claimable costs $39.95. No success fees, no hidden costs – just a flat fee. If your migraine medication runs $1,000+ per month without coverage, the math speaks for itself.

Start your Ubrelvy appeal →

Appeal Timelines: How Long Does an Ubrelvy Appeal Take?

Submitting a complete, well-documented appeal from the start is the single best way to speed up the process. Incomplete submissions get delayed by requests for additional information. The average Claimable appeal gets a response in just 10 days.

FAQs

Why was my Ubrelvy denied if my doctor prescribed it?

A prescription and an insurance approval are two different things. Most plans require prior authorization for Ubrelvy, and those PA criteria often include step therapy requirements (trying triptans first), quantity limits, and documentation thresholds that go beyond what your doctor submits with a standard prescription. Your doctor determined Ubrelvy is right for you medically – the insurer is applying a separate, often more restrictive, set of criteria.

What if I can't take triptans — do I still have to try them before getting Ubrelvy?

No – and this is one of the strongest appeal arguments for Ubrelvy. If you have cardiovascular conditions that contraindicate triptans, or documented intolerance or side effects from prior triptan use, those count as "failure" under most step therapy policies. Your appeal should include specific documentation of why triptans are inappropriate for you. The insurer cannot require you to take a medication that your doctor has determined is medically unsafe.

Can I appeal an Ubrelvy denial myself, or does my doctor have to do it?

You can appeal yourself. Patient-initiated appeals carry their own legal protections – mandated response timelines, the right to escalate to external review, and multiple appeal levels. Your appeal is separate from anything your doctor's office files and doesn't depend on your doctor's appeal being successful.

Can I take Ubrelvy with an injectable CGRP medication like Aimovig or Emgality?

Published clinical evidence supports using Ubrelvy for acute treatment alongside a CGRP monoclonal antibody for prevention. They target different aspects of the CGRP pathway and serve different clinical purposes. If your insurer denied Ubrelvy based on "duplicate CGRP therapy," a clinical rationale from your neurologist citing the published safety data is typically the path to overturning it.

What's the difference between the 50mg and 100mg dose?

Both strengths are FDA-approved and showed similar pain freedom rates in clinical trials (21% at 2 hours for both 50mg and 100mg vs. 13% for placebo). For freedom from the most bothersome migraine symptoms – which includes nausea, sensitivity to light, and sensitivity to sound – rates were 38% for the 100mg tablet vs. 28% for placebo. The 100mg strength was also used in the PRODROME trial studying treatment during the early warning signs of a migraine and is often prescribed for patients with more severe attacks. Dose adjustments may also be needed based on other medications you take or kidney/liver function. If your insurer approved only the 50mg, your prescriber can submit a clinical rationale for the higher strength.

How many tablets of Ubrelvy should I be prescribed?

Ubrelvy's prescribing information establishes safety for treating up to 8 migraines per 30-day period, with the option for a second dose per attack. That means patients may need anywhere from 8 to 16 tablets per month depending on migraine frequency and whether a second dose is typically required. Insurer quantity limits vary: Some cap at 8 tablets, others at 10 or 16. If your prescribed quantity was denied, a quantity override request with clinical justification from your prescriber is the standard next step.

Is Ubrelvy the same as Nurtec?

No. Both are oral calcitonin gene-related peptide medications used in the treatment of migraines, but they're different drugs with different approvals. Ubrelvy (ubrogepant) is approved only for acute treatment, stopping a migraine attack in progress. Nurtec ODT (rimegepant) is approved for both acute treatment and prevention of episodic migraine. They also have different drug interaction profiles and dosing schedules. Other CGRP medications in the migraine landscape include Qulipta (atogepant), which is approved only for prevention, and Zavzpret (zavegepant), a nasal spray approved only for acute treatment. If your insurer wants you to switch to a different CGRP medication, your appeal should explain why Ubrelvy is the more appropriate choice for your specific situation.

How much does Ubrelvy cost without insurance?

The manufacturer's list price is approximately $1,085 for a month's supply. Retail prices can run higher, averaging around $1,300 for 10 tablets at some pharmacies. AbbVie offers the UBRELVY Complete Savings Card for commercially insured patients, which can reduce costs to as little as $0 per monthly fill (up to $7,000 in annual savings). Patients without commercial insurance who meet income requirements may qualify for AbbVie's patient assistance program (myAbbVie Assist), which provides the medication at no cost.

Is it worth appealing an Ubrelvy denial?

Absolutely. Insurers count on patients accepting a denial as final – fewer than 1% of denied claims are ever challenged. But appeals exist because denials are frequently wrong: documentation was incomplete, criteria were misapplied, or the insurer ignored clinical evidence. Your doctor prescribed Ubrelvy because you need it. The appeal is your opportunity to prove that case with the right evidence, the right arguments, and the right legal framework behind you.

Claimable's physician-led team has helped patients recover millions in care access by fighting insurance denials. We're SOC 2 Type II certified and HIPAA compliant. Learn more about how Claimable works →

Related: Why Was My Migraine Treatment Denied? Common Insurance Denial Reasons and How to Fight Back